which limits access of tumor-killing T cells. Because of that so-called immune desert environment, pancreatic ductal adenocarcinoma (PDA), the most common type of pancreatic cancer, has been ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.

Across the solid-tumor spectrum, many patients are burdened with metastatic, immune-excluded or immune-desert tumors that do not respond to checkpoint monoclonal antibodies. Systemically ...

A new type of antibody which stimulates the immune system to target cancer cells slows tumour growth, according to new research.

A new review article published in Genes & Diseases sheds light on the complex molecular mechanisms through which ...

Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of ...

For decades, scientists have explored the potential of bacteria in fighting cancer, but safety and efficacy barriers have ...

Pancreatic cancer remains one of the most challenging tumors to treat, partly because it is often discovered at advanced stages when the disease has already spread, or metastasized. About half of ...